基本信息
浏览量:194
职业迁徙
个人简介
Areas of expertise: Melanoma research; Susceptibility to melanoma; factors moderating melanoma survival
In 1995 I moved to Leeds. Since then I have worked with Professor Tim Bishop and a group of experienced technicians and statisticians and the group is now formally part of the Immunology subgroup of the Institute of Medical Research at St James's. The research funding has been primarily from ICRF and then Cancer Research UK, as consecutive programme grants. We have benefitted however from three consecutive collaborative NIH R01s, a MRC project grant, a large Network of Excellence grant from the EU under Framework 6, and smaller grants from charities such as Melanoma Focus, the Skin Diseases Research Fund and the AICR. In 2000 we broadened the research aims to ask what inherited, somatic tumour events and exposures moderate melanoma survival. We have built very large cohorts in order to address these aims.
I played a key role in establishing UK and European Clinical Guidelines, and have been involved in other UK committees designed to inform management. 2004-2005 I was a member of the NICE Skin Cancer Guideline Committee, 2012-2015 I was the clinical chair for the NICE Melanoma Clinical Guideline. I was chairman of the NCIN Skin Cancer Committee from 2009-2014 during which we defined the COSD data sets.
In 1997 I instigated and have since then been chairman of the international melanoma genetics consortium GenoMEL. This consortium has led the way internationally in the identification of common and rare inherited genetic variants associated with melanoma risk. This is important in terms of understanding the biology of melanoma aetiology, giving insight into prevention, and for the rare high penetrance genes the long-term aim is to understand risk and to instruct proper screening programmes.
Responsibilities
Lead Melanoma Research Group
Leeds Institute of Medical Research at St James’s
Research interests
I lead a research group in the Institute of Medical Research at St James's which is part of the University of Leeds. The research group uses epidemiology and genomics (of the germline and tumour) to understanding susceptibility to melanoma and survival from melanoma.
We have published extensively on high-risk susceptibility genes and more recently on large genome wide association studies designed to identify low to medium penetrance susceptibility genes. I have been Chairman of the international melanoma genetics consortium GenoMEL since 1997. Under my leadership the consortium has successfully obtained funding from the NIH and from the EU under FP6. The EU grant was for 10.5 million euros. This research has produced 4 Nature Genetics papers in the last 3 years.
Just as susceptibility to cancer is governed by heredity, and the environment, our hypothesis is that the probability of survival for cancer patients is also modified by heredity and the environment as well as variation in the biological characteristics of the tumours themselves. Current research in Leeds is directed toward understanding these modifiers. I have set up a second consortium called BioGenoMEL, and this consortium was created in order to pool data from research groups internationally to generate enough statistical power to identify inherited genetic variation having an effect on melanoma survival. By finding genetic variation which modifies survival expectation, we will identify important biological processes governing host/tumour interaction which may promote the recognition of novel therapies for cancer.
The focus of the research in recent years has shifted to include the aim of understanding environmental factors which modify that interaction between the patient and his/her tumour. In order to do that we have built very large cohort studies: collecting complex data sets on lifestyles, blood samples and tumour samples from melanoma patients. We are grateful to those patients for their time and willingness to donate their samples. The largest study is known as the Leeds Melanoma Cohort in which 2184 patients participated see plain English summary below https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-why-melanoma-skin-cancer-comes-back-after-surgery
We have reported evidence that smoking reduces survival in melanoma patients and that this is most marked in patients whose tumours contain a stronger immune reaction: something that usually increases the expectation of survival (Pozniak et al Cancer Research in press 2019). We first reported evidence that higher vitamin D levels at melanoma diagnosis was associated with thinner tumours and better survival in 2009. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19770375.
These findings have since been recapitulated in other studies from the USA, Germany and Australia. We continue to work on studies designed to understand the biological processes associated with the association between vitamin D and better melanoma survival.
In 1995 I moved to Leeds. Since then I have worked with Professor Tim Bishop and a group of experienced technicians and statisticians and the group is now formally part of the Immunology subgroup of the Institute of Medical Research at St James's. The research funding has been primarily from ICRF and then Cancer Research UK, as consecutive programme grants. We have benefitted however from three consecutive collaborative NIH R01s, a MRC project grant, a large Network of Excellence grant from the EU under Framework 6, and smaller grants from charities such as Melanoma Focus, the Skin Diseases Research Fund and the AICR. In 2000 we broadened the research aims to ask what inherited, somatic tumour events and exposures moderate melanoma survival. We have built very large cohorts in order to address these aims.
I played a key role in establishing UK and European Clinical Guidelines, and have been involved in other UK committees designed to inform management. 2004-2005 I was a member of the NICE Skin Cancer Guideline Committee, 2012-2015 I was the clinical chair for the NICE Melanoma Clinical Guideline. I was chairman of the NCIN Skin Cancer Committee from 2009-2014 during which we defined the COSD data sets.
In 1997 I instigated and have since then been chairman of the international melanoma genetics consortium GenoMEL. This consortium has led the way internationally in the identification of common and rare inherited genetic variants associated with melanoma risk. This is important in terms of understanding the biology of melanoma aetiology, giving insight into prevention, and for the rare high penetrance genes the long-term aim is to understand risk and to instruct proper screening programmes.
Responsibilities
Lead Melanoma Research Group
Leeds Institute of Medical Research at St James’s
Research interests
I lead a research group in the Institute of Medical Research at St James's which is part of the University of Leeds. The research group uses epidemiology and genomics (of the germline and tumour) to understanding susceptibility to melanoma and survival from melanoma.
We have published extensively on high-risk susceptibility genes and more recently on large genome wide association studies designed to identify low to medium penetrance susceptibility genes. I have been Chairman of the international melanoma genetics consortium GenoMEL since 1997. Under my leadership the consortium has successfully obtained funding from the NIH and from the EU under FP6. The EU grant was for 10.5 million euros. This research has produced 4 Nature Genetics papers in the last 3 years.
Just as susceptibility to cancer is governed by heredity, and the environment, our hypothesis is that the probability of survival for cancer patients is also modified by heredity and the environment as well as variation in the biological characteristics of the tumours themselves. Current research in Leeds is directed toward understanding these modifiers. I have set up a second consortium called BioGenoMEL, and this consortium was created in order to pool data from research groups internationally to generate enough statistical power to identify inherited genetic variation having an effect on melanoma survival. By finding genetic variation which modifies survival expectation, we will identify important biological processes governing host/tumour interaction which may promote the recognition of novel therapies for cancer.
The focus of the research in recent years has shifted to include the aim of understanding environmental factors which modify that interaction between the patient and his/her tumour. In order to do that we have built very large cohort studies: collecting complex data sets on lifestyles, blood samples and tumour samples from melanoma patients. We are grateful to those patients for their time and willingness to donate their samples. The largest study is known as the Leeds Melanoma Cohort in which 2184 patients participated see plain English summary below https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-why-melanoma-skin-cancer-comes-back-after-surgery
We have reported evidence that smoking reduces survival in melanoma patients and that this is most marked in patients whose tumours contain a stronger immune reaction: something that usually increases the expectation of survival (Pozniak et al Cancer Research in press 2019). We first reported evidence that higher vitamin D levels at melanoma diagnosis was associated with thinner tumours and better survival in 2009. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19770375.
These findings have since been recapitulated in other studies from the USA, Germany and Australia. We continue to work on studies designed to understand the biological processes associated with the association between vitamin D and better melanoma survival.
研究兴趣
论文共 273 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Lucy Godson, Navid Alemi,Jérémie Nsengimana,Graham P Cook,Emily L Clarke,Darren Treanor,D Timothy Bishop,Julia Newton-Bishop,Ali Gooya,Derek Magee
Medical image analysis (2024): 103097-103097
Juliette Randerson-Moor,John Davies,Mark Harland,Jérémie Nsengimana, Theophile Bigirumurame, Christopher Walker,Jon Laye, Elizabeth S, Appleton,Graham Ball,Graham P. Cook,D Timothy Bishop,Robert J. Salmond,
Nature Medicineno. 3 (2024): 785-796
Cancer Researchno. 6_Supplement (2024): 3020-3020
Emily L. Clarke,Derek Magee,Julia Newton-Bishop, William Merchant, Marlous Hall, Robert Insall, Nigel Maher,Richard Scolyer, Grace Farnworth, Anisah Ali, Sally O'Shea,Darren Treanor
Cancer Researchno. 6_Supplement (2024): 6173-6173
Charles H. Earnshaw,Shih-Chieh Chiang,Agrin Moeini, Maria Koufaki,Eduardo Bonavita, Laetitia Nebot-Bral, Massimo Russo,Charlotte Bell, Theophile Bigirumurame,Jérémie Nsengimana,Julia Newton-Bishop, Christopher E. Griffiths,
Cancer Researchno. 6_Supplement (2024): 2647-2647
Scientific Reportsno. 1 (2023): 1-9
Julia A. Newton-Bishop,Yu-Mei Chang,Mark M. Iles,John C. Taylor, Bert Bakker,May Chan, Susan Leake, Birute Karpavicius, Sue Haynes, Elaine Fitzgibbon,Faye Elliott,Peter A. Kanetsky,
crossref(2023)
Authorea (Authorea)no. 8 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn